141 results on '"Pinto, Donald J"'
Search Results
2. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor
3. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
4. N-in-1 Dosing Pharmacokinetics in Drug Discovery: Experience, Theoretical and Practical Considerations
5. Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.
6. Effect of Lung Volume Reduction Surgery on Diaphragmatic Neuromechanical Coupling At 2 Years
7. A double antibody radioimmunoassay for the determination of XV459, the active hydrolysis metabolite of roxifiban, in human plasma
8. Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups
9. Effect of Lung Volume Reduction Surgery on Neuromechanical Coupling of the Diaphragm
10. Factor XIa Inhibitors as New Anticoagulants
11. Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)
12. Abstract TMP117: Preclinical and Early Clinical Characterization of a Parenterally Administered Direct Factor XIa Inhibitor
13. Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker
14. Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups
15. Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)
16. The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review
17. Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma
18. ChemInform Abstract: Terphenyl Cyclooxygenase-2 (COX-2) Inhibitors: Optimization of the Central Ring and o-Biphenyl Analogues.
19. ChemInform Abstract: Isoxazolines and Isoxazoles as Factor Xa Inhibitors.
20. ChemInform Abstract: Synthesis and SAR of Benzamidine Factor Xa Inhibitors Containing a Vicinally-Substituted Heterocyclic Core.
21. Factor Xa Inhibitors: Next-Generation Antithrombotic Agents
22. Sulfation of O-Demethyl Apixaban: Enzyme Identification and Species Comparison
23. Dose-Dependent Antithrombotic Effects of Apixaban, an Oral Direct Factor Xa Inhibitor, in Prevention and Treatment of Thrombosis in Rabbit Models of Arteriovenous-Shunt and Venous Thrombosis at Doses That Preserve Hemostasis.
24. The Direct Factor Xa Inhibitor Apixaban Produces Broad Antithrombotic Activity with Limited Effects on Bleeding Time in Rats.
25. Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa
26. 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6- [2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl- [1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-on# e (I) (BMS-740808) a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa.
27. Effects of the Factor Xa Inhibitor Apixaban on Venous Thrombosis and Hemostasis in Rabbits.
28. In Vitro Evaluation of Apixaban, a Novel, Potent, Selective and Orally Bioavailable Factor Xa Inhibitor.
29. Preclinical Pharmacokinetic and Metabolism of Apixaban, a Potent and Selective Factor Xa Inhibitor.
30. Nonpeptide Factor Xa Inhibitors: DPC423, a Highly Potent and Orally Bioavailable Pyrazole Antithrombotic Agent
31. Discovery of 1-(3‘-Aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor
32. Discovery of 1-(2-Aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2‘-(aminosulfonyl)[1,1‘-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor
33. Structure-Based Design of Novel Guanidine/Benzamidine Mimics: Potent and Orally Bioavailable Factor Xa Inhibitors as Novel Anticoagulants
34. Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in Rabbits
35. Disposition of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2‘- (methylsulfonyl)-[1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)- 1H-pyrazole-5-carboxamide (DPC 423) by Novel Metabolic Pathways. Characterization of Unusual Metabolites by Liquid Chromatography/Mass Spectrometry and NMR
36. Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core
37. Discovery of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2‘-(methylsulfonyl)- [1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa
38. Isoxazolines and isoxazoles as factor Xa inhibitors
39. Orally Active Isoxazoline Glycoprotein IIb/IIIa Antagonists with Extended Duration of Action
40. Structure-activity relationships (SAR) of some tetracyclic heterocycles related to the immunosuppressive agent brequinar sodium
41. Discovery of an Orally Active Series of Isoxazoline Glycoprotein IIb/IIIa Antagonists
42. The Discovery of Potent Isoxazoline Glycoprotein IIb/IIIa Receptor Antagonists
43. Discovery of Potent Isoxazoline Glycoprotein IIb/IIIa Receptor Antagonists
44. Immunosuppressive structure-activity relationships of Brequinar and related cinchoninic acid derivatives
45. Metabolism resistant isothiazolone inhibitors of cartilage breakdown
46. Synthesis, chemical, and biological properties of vinylogous hydroxamic acids: dual inhibitors of 5-lipoxygenase and IL-1 biosynthesis
47. Vinylogous hydroxamic acids: 5-lipoxygenase inhibitors
48. Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma.
49. Nonpeptide Factor Xa Inhibitors: DPC423, a Highly Potent and Orally Bioavailable Pyrazole Antithrombotic Agent.
50. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.